Indo Us Biotech Limited (INDOUS) reported revenue of ₹32.99 Cr and net profit of ₹3.04 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
INDOUS fundamentals, Fundamental score 56/100
The statements below are read from Indo Us Biotech Limited’s filed results, 13 filed quarters and 12 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 13, 2026 · audited
Sales CAGR · 3Y+21.9%FY22 → FY25
Sales CAGR · 4Y+22.5%FY21 → FY25
PAT CAGR · 3Y+23.3%FY22 → FY25
PAT CAGR · 4Y+27.3%FY21 → FY25
Price · 1Y−46.5%EOD
Price CAGR · 3Y—EOD
Showing standalone — consolidated filings end FY21-22.
Quarterly resultsStandalone
₹ Cr
Jun2022
Sep2022
Dec2022
Mar2023
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
14.4
13.7
15.5
18.1
24.7
22.2
23.6
33.4
30.8
30.8
22.8
26.0
33.0
+7.2%
12.6
12.2
14.2
16.0
21.0
17.1
18.0
28.8
25.3
26.7
18.6
22.8
29.0
+14.7%
Operating profit
—
—
—
—
3.69
5.12
5.54
4.58
5.47
4.16
4.15
3.23
3.96
-27.6%
OPM %
—
—
—
—
14.9%
23.1%
23.5%
13.7%
17.8%
13.5%
18.2%
12.4%
12.0%
-5.8 pp
Other income
0.00
-0.00
0.00
0.02
0.03
0.02
0.02
0.12
0.00
0.03
0.01
0.02
0.12
n/m
Interest
—
—
—
—
0.33
0.52
0.38
0.26
0.45
0.42
0.77
0.60
0.74
+63.9%
Depreciation
—
—
—
—
0.20
0.18
0.16
0.56
0.20
0.21
0.22
0.27
0.27
+34.2%
Profit before tax
1.80
1.60
1.35
2.14
3.19
4.45
5.02
3.88
4.82
3.56
3.16
2.38
3.08
-36.2%
Tax %
—
18.8%
-1.3%
1.7%
0.6%
1.9%
-0.7%
5.0%
2.4%
3.0%
5.3%
17.1%
1.3%
-1.2 pp
Net profit
1.80
1.30
1.37
2.10
3.17
4.36
5.05
3.68
4.70
3.45
3.00
1.97
3.04
-35.4%
EPS (₹)
—
—
—
—
—
2.16
—
1.86
2.35
1.72
1.49
0.98
1.51
-35.7%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 13 quarters
RevenueNet profit
Revenue & net profit — Standalone13 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±3.4%· EPS surprise: no estimates source· 5 earlier quarters have no dated filing on record
Q1'27filed Wed 12 Aug 15:23 · traded that sessiongap +3.0%close −0.0%
Q4'26filed Fri 29 May 18:19 · first tradeable session Mon 1 Jungap −1.8%close −0.0%
Q3'26filed Wed 21 Jan 15:18 · traded that sessiongap −2.4%close +2.5%
Q2'26filed Fri 14 Nov 16:56 · first tradeable session Mon 17 Novgap −1.9%close −4.5%
Q1'26filed Tue 12 Aug 14:43 · traded that sessiongap +3.2%close +3.1%
Q4'25filed Tue 27 May 16:22 · first tradeable session Wed 28 Maygap +4.7%close +4.7%
Q3'25filed Tue 11 Feb 14:43 · traded that sessiongap +1.8%close −2.3%
Q2'25filed Thu 14 Nov 12:50 · traded that sessiongap +1.7%close +9.8%
